Evidence map›Paper›PMID 39472530›Full record

ArticleScientific reports2024

pH-responsive magnetic CuFe

Nadia Fattahi, Faranak Aghaz, Aram Rezaei, Ali Ramazani, Abolfazl Heydari, Seyedmohammad Hosseininezhad, Won-Kyo Jung

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Stimuli-responsive bioengineered platforms for precision cancer therapy.Frontiers in bioengineering and biotechnology · 2026
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nadia FattahiThe Organic Chemistry Research Laboratory (OCRL), Department of Chemistry, Faculty of Science, University of Zanjan, Zanjan, 45371-38791, Iran.
Faranak AghazNano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, 67158-47141, Iran.
Aram RezaeiNano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, 67158-47141, Iran. aram.rezaei@gmail.com.
Ali RamazaniThe Organic Chemistry Research Laboratory (OCRL), Department of Chemistry, Faculty of Science, University of Zanjan, Zanjan, 45371-38791, Iran. aliramazani@gmail.com.
Abolfazl HeydariPolymer Institute of the Slovak Academy of Sciences, Dúbravská cesta 9, Bratislava, 845 41, Slovakia.
Seyedmohammad HosseininezhadThe Organic Chemistry Research Laboratory (OCRL), Department of Chemistry, Faculty of Science, University of Zanjan, Zanjan, 45371-38791, Iran.
Won-Kyo JungMarine Integrated Biomedical Technology Center, The National Key Research Institutes in Universities, Pukyong National University, Busan, 48513, Republic of Korea. wkjung@pknu.ac.kr.

Funding

Kermanshah University of Medical Sciences 990592
6 · The paper itself

Abstract

In this study, a novel magnetic and pH-responsive nanocarrier was developed, incorporating both natural and synthetic polymers, for delivering curcumin (CUR) to breast cancer cells. For this purpose, CuFe

Indexed as

Breast NeoplasmsCopperLigninAntineoplastic AgentsCell SurvivalCurcuminDrug CarriersDrug Delivery SystemsDrug LiberationFemaleHumansHydrogen-Ion ConcentrationMCF-7 CellsNanogelsPolyethylene GlycolsPolymethacrylic AcidsAntineoplastic AgentsCopperCurcuminDrug CarriersLigninNanogelsPolyethylene Glycolspolymethacrylic acidPolymethacrylic Acidsantitumor activitydrug deliveryligninNanogelpH-responsive

Identifiers

PMID39472530
PMCPMC11522326

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.